Hao Siguo, Ye Zhenmin, Yang Jicheng, Bai Ou, Xiang Jim
Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Cancer Biother Radiopharm. 2006 Apr;21(2):146-54. doi: 10.1089/cbr.2006.21.146.
Because dendritic cell (DC)-derived exosomes (EXO) harbor many important DC molecules involved in inducing immune responses, EXO-based vaccines have been extensively used to induce antitumor immunity in different animal tumor models. However, it is not clear which route of EXO administration can induce more efficient antitumor immune responses. In this study, we compared the antitumor immunity derived from EXO vaccine by way of the two common administration routes, the subcutaneous (s.c.) and the intradermal (i.d.) administrations. Our data showed that the i.d. EXO administration resulted in more EXO-absorbed DC migrating into the T-cell areas of draining lymph nodes than the s.c. administration. Interestingly, the i.d. EXO administration also resulted in an enhanced ovalbumin (OVA)-specific CD8(+) T-cell proliferation and CD8(+) CTL effector responses in vivo, compared to the s.c. administration. Similarly, compared to the s.c. vaccination, the i.d. vaccination induced stronger antitumor immunity in the animal tumor model. Therefore, the i.d. EXO vaccination is superior to the s.c. one and should be considered when EXO-based vaccine is designed.
由于树突状细胞（DC）来源的外泌体（EXO）含有许多参与诱导免疫反应的重要DC分子，基于EXO的疫苗已被广泛用于在不同动物肿瘤模型中诱导抗肿瘤免疫。然而，尚不清楚哪种EXO给药途径能诱导更有效的抗肿瘤免疫反应。在本研究中，我们比较了通过皮下（s.c.）和皮内（i.d.）这两种常见给药途径给予EXO疫苗所产生的抗肿瘤免疫。我们的数据表明，与皮下给药相比，皮内给予EXO会使更多摄取EXO的DC迁移至引流淋巴结的T细胞区域。有趣的是，与皮下给药相比，皮内给予EXO在体内还能增强卵清蛋白（OVA）特异性CD8(+) T细胞增殖和CD8(+) CTL效应反应。同样，与皮下接种疫苗相比，皮内接种疫苗在动物肿瘤模型中诱导出更强的抗肿瘤免疫。因此，皮内给予EXO疫苗优于皮下给予，在设计基于EXO的疫苗时应予以考虑。
